AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05565105
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan: 70 mg/m\^2/day x 2
Trial: NCT05565105
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine: 25 mg/m\^2/day x 5
Trial: NCT05674864
Drug: Bifidobacterium Infants plus Enterococcus Feacium plus Lactobacillus Acidophilus
RxNorm normalized name: Bifidobacterium animalis / Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium Infants, Enterococcus Feacium, and Lactobacillus Acidophilus combination will be given as one capsule three times daily for 14 days
Trial: NCT06425419
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
Trial: NCT04801940
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 2.5mg orally twice daily for 14 days.
Trial: NCT04801940
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg orally once daily for 12 months.
Trial: NCT06619015
Drug: Pramlintide Acetate 1 MG/ML
RxNorm normalized name: pramlintide acetate 1 MG/ML
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Symlin (R) (Pramlintide acetate) 1000mcg/ml, will be administered as a continuous infusion at a rate of 15mcg/hour, equivalent to the daily recommended maximum dosage of 360mcg/day.
Trial: NCT06619015
Drug: Semaglutide Pen Injector
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide from 0,25mg/week to 2,4mg/week
Trial: NCT05981118
Drug: Betamethasone dipropionate 0.05%
RxNorm normalized name: BETAMETHASONE DIPROPIONATE 0.05% OINT
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05% cream group will be treated once daily on both legs until clear or up to 12 weeks
Trial: NCT05981118
Drug: Tapinarof
RxNorm normalized name: Tapinarof
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks
Trial: NCT06619015
Drug: Sodium Chloride 0.9% Inj
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04774926
Drug: Brolucizumab
RxNorm normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 120 mg/ml solution for intravitreal injection
Trial: NCT06255366
Drug: Caroxime sodium sulfonate
RxNorm normalized name: Sodium Polystyrene Sulfonate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.
Trial: NCT06255366
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery
Trial: NCT06255366
Drug: 0.9% Sodium Chloride Injection
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery
Trial: NCT05696847
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06186076
Drug: TRX-221
RxNorm normalized name: TRX-0237
DrugBank: Hydromethylthionine mesylate (DB16899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRX-221 oral dose as defined
Trial: NCT06027437
Drug: Danicamtiv
RxNorm normalized name: Danicamtiv
DrugBank: Danicamtiv (DB18962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days.
Trial: NCT04698850
Drug: Aflibercept 40 MG/ML [Eylea]
RxNorm normalized name: aflibercept 40 MG/ML [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be receiving intravitreal aflibercept starting with 3 monthly doses and continuing with treat-and-extend regimen with minimal interval of 8 week and maximum interval of 16 week. Interval can be prolonged or shortened by 2 or 4 weeks based on the disease activity and BCVA..
Trial: NCT04698850
Drug: Brolucizumab-Dbll 120 MG/ML [Beovu]
RxNorm normalized name: brolucizumab-dbll 120 MG/ML [Beovu]
DrugBank: Brolucizumab (DB14864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be receiving intravitreal brolucizumab starting with 3 monthly doses followed by the treatment interval of 8 or 12 weeks based on the disease activity and BCVA.
Trial: NCT04698850
Drug: Ranibizumab 6 MG/ML [Lucentis]
RxNorm normalized name: ranibizumab 6 MG/ML [Lucentis]
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rescue therapy for patients with study drug related adverse events or with worsening of BCVA and OCT finding even on the shortest treatment interval when resistance to study drug is suspected.
Trial: NCT05347147
Drug: Presendin
RxNorm normalized name: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
DrugBank: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (DB15813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presendin is supplied as 2 parts, one vial consisting of a drug part (white or greyish white powder in a clear vial) and one pre-filled syringe containing the diluent part (colourless liquid). The drug part is suspended in the diluent part solution and administered SC as a suspension.
Trial: NCT06500052
Drug: BL-M17D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT05658107
Drug: BI 765423
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 765423
Trial: NCT05926492
Drug: Surufatinib plus chemotherapy
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib: (1) for patients aged \> 21 years old and ≤70 years old, surufatinib 200 mg, qd, oral, continuous administration; (2) For patients aged ≥2 years and ≤21 years, starting from the low dose of patient BSA (body surface area), Stevenson's formula developed according to the Chinese population was used: BSA = 0.0061H+0.0128W-0.1529 (H: BSA = 0.0061H+0.0128W-0.1529). Height /cm; W: body weight /kg); Chemotherapy : 1) Doxorubicin 60 mg/m2, or liposome doxorubicin 45mg/ m2, day 17; 2) Cisplatin: 100 mg/m2, day 15; 3) Ifosfamide; 2.5g/m2, day 8-12;~The above drugs were used in turn, and 30 days were regarded as a treatment cycle.
Trial: NCT04824144
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).
Trial: NCT05960708
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of Omalizumab
Trial: NCT06542731
Drug: ONO-4578
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06542731
Drug: ONO-4538
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06542731
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06542731
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT05748483
Drug: Atogepant
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05748483
Drug: Placebo for Atogepant
RxNorm normalized name: Atogepant
DrugBank: Atogepant (DB16098)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05748483
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Capsule
Trial: NCT05748483
Drug: Placebo for Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Capsule
Trial: NCT05012098
Drug: Bintrafusp alfa / M7824
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be treated with bintrafusp alfa 1200 mg every 2 weeks for 26 doses.
Trial: NCT06700421
Drug: Adebrelimab + Apatinib
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab combined with apatinib
Trial: NCT05149807
Drug: SHR-1701 injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1701 injection Tegafur Gimeracil Oteracil Potassium Oxaliplatin
Trial: NCT05247489
Drug: Ruxolitinib 1.5% cream
RxNorm normalized name: RUXOLITINIB 1.5% CREAM,TOP
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream 1.5% applied twice a day (BID).
Trial: NCT06123494
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1811 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
Trial: NCT06123494
Drug: Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ramucirumab 8mg/kg，D 1,15 + Paclitaxel 80mg/m2，D1,8,15，Q4W; Paclitaxel 80mg/m2，D1,8,15，Q4W; Docetaxel 75mg/m2，D1，Q3W; Irinotecan 150mg/m2，D1，Q2W.
Trial: NCT06347471
Drug: Dihydroartemisinin-Piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the DHA-PPQ arm will be treated with standard doses of DHA-PPQ. Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau or Duocotecxin, Beijing Holley-Cotect Pharmaceutical Co) will be administered per manufacturer guidelines. All doses will be given under direct supervision on an empty stomach, as per manufacturer instructions.
Trial: NCT05515367
Drug: Desidustat
RxNorm normalized name: Desidustat
DrugBank: Desidustat (DB16135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04626141
Drug: Abaloparatide
RxNorm normalized name: Abaloparatide
DrugBank: Abaloparatide (DB05084)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
Trial: NCT04876781
Drug: Tofacitinib XR
RxNorm normalized name: tofacitinib Extended Release Oral Tablet
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tofacitinib XR 11mg
Trial: NCT06312761
Drug: Relugolix 120Mg Tab
RxNorm normalized name: RELUGOLIX 120MG TAB
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relugolix 120 mg single dose - All subjects
Trial: NCT06103864
Drug: Dato-DXd
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided in 100mg vials. IV infusion. Experimental drug.
Trial: NCT06103864
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Provided in 500mg vials. IV infusion. Experimental drug.
Trial: NCT06103864
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion. Active comparator.
Trial: NCT06103864
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion. Active comparator.
Trial: NCT06103864
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion. Active comparator.
Trial: NCT06103864
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion. Active comparator.
Trial: NCT06103864
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion. Active comparator.
Trial: NCT06516445
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, D1, ivgtt, Q3W, C1-4
Trial: NCT06516445
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, BID, PO, Q3W, C1-4
Trial: NCT05073094
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esmolol injected intravenously and added to cardioplegia solution
Trial: NCT04951323
Drug: anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
RxNorm normalized name: ChulaCov19 mRNA vaccine
DrugBank: ChulaCov19 mRNA vaccine (DB16445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the COVID-19 mRNA Vaccine BNT162b2 (Comirnaty®). The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
Trial: NCT05093374
Drug: anti-VEGF agent
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~Presence/change of sub- and intraretinal fluid will be assessed objectively by AI software and the results will be provided during the visit to the investigator. The final decision for/against retreatment is always made by the discretion of the clinical investigator. Should the Investigators decision differ from the study protocol, the reason will be indicated in the CRF.
Trial: NCT05093374
Drug: anti-VEGF agent
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will be treated at baseline. A loading dose of 2 additionally monthly treatments will be performed at months 1 and 2. Patients showing no intra- and/or subretinal fluid in the central 1mm subfield at month 1, no treatment will be given till any disease activity is documented.~In this cohort the amount of retinal fluid will not be assessed by AI software at the time of retreatment.
Trial: NCT05037409
Drug: PF-06823859
RxNorm normalized name: Immunoglobulin G1 [236-alanine,237-alanine,239-alanine,de-C-terminal-lysine], anti-(human interferon β) (human-Mus musculus monoclonal PF-06823859 γ1-chain), disulfide with human-Mus musculus monoclonal PF-06823859 κ-chain, dimer
DrugBank: Dazukibart (DB18429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose or high dose intravenous infusion
Trial: NCT04939662
Drug: Olaparib+Bevacizumab to SCLC patients
RxNorm normalized name: Olaparib
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW.
Trial: NCT04335292
Drug: Platinum + Pemetrexed Chemotherapy Second-Line
RxNorm normalized name: platinum
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.
Trial: NCT04915144
Drug: 177Lu-DOTATOC
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
Trial: NCT05123040
Drug: Ruxolitinib 10 MG Oral Tablet
RxNorm normalized name: ruxolitinib 10 MG Oral Tablet
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: By mouth twice daily through day 56, then tapered
Trial: NCT05123040
Drug: hCG
RxNorm normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses
Trial: NCT06528691
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally (PO) or enterally
Trial: NCT06528691
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06528691
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06373978
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg every 8hours as needed for pain
Trial: NCT05862714
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg stat. Follow up at 4 weeks
Trial: NCT05862714
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg stat. Follow up at 4 weeks
Trial: NCT04828083
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine of 1.5 mg/kg bolus followed by a 1.5 mg/kg/h infusion continuing to the end of phase 1 of post anesthesia care unit
Trial: NCT06703580
Drug: Hyperbaric prilocaine 2% 40 mg
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in a dose of 40 mg.
Trial: NCT06703580
Drug: hyperbaric prilocaine 2% 50 mg
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of 3 different doses of prilocaine
Trial: NCT06703580
Drug: hyperbaric prilocaine 2% 60 mg
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: this study compare 3 different doses of prilocaine
Trial: NCT06702488
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.
Trial: NCT04762901
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet
Trial: NCT04762901
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT04762901
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Injection
Trial: NCT04762901
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT05761756
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of methylphenidate
Trial: NCT05761756
Drug: Carbon Dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
Trial: NCT04996875
Drug: bezuclastinib
RxNorm normalized name: Bezuclastinib
DrugBank: Bezuclastinib (DB18041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezuclastinib is administered as tablets to be taken orally, continuously in 28-day cycles.
Trial: NCT06448026
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by IV
Trial: NCT06448026
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV
Trial: NCT05110144
Drug: Duloxetine 30 MG
RxNorm normalized name: duloxetine 30 MG
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg orally for 4 weeks